Heron Therapeutics, Inc.
HRTX
$0.84
-$0.03-3.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.20M | -13.58M | -931.00K | -7.79M | -13.58M |
| Total Depreciation and Amortization | 2.31M | 2.36M | 2.32M | 2.35M | 2.49M |
| Total Amortization of Deferred Charges | 817.00K | 913.00K | 1.09M | 1.03M | 961.00K |
| Total Other Non-Cash Items | 21.35M | 21.28M | 9.91M | 14.49M | 15.20M |
| Change in Net Operating Assets | -31.88M | -41.16M | -40.54M | -31.97M | -27.60M |
| Cash from Operations | -27.59M | -30.19M | -28.15M | -21.88M | -22.53M |
| Capital Expenditure | -317.00K | -955.00K | -1.39M | -1.82M | -1.71M |
| Sale of Property, Plant, and Equipment | 98.00K | 109.00K | 80.00K | 69.00K | 27.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 16.23M | 33.73M | 26.30M | 21.46M | 20.39M |
| Cash from Investing | 16.01M | 32.88M | 25.00M | 19.71M | 18.71M |
| Total Debt Issued | 137.25M | 142.04M | -- | -- | -- |
| Total Debt Repaid | -150.00M | -150.00M | -- | -- | -- |
| Issuance of Common Stock | 20.63M | 21.06M | 1.35M | 940.00K | 940.00K |
| Repurchase of Common Stock | -1.31M | -- | -- | -- | -- |
| Issuance of Preferred Stock | 7.86M | 7.86M | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -6.32M | -70.00K | 53.00K | 0.00 |
| Cash from Financing | 14.43M | 14.63M | 1.28M | 993.00K | 940.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.85M | 17.33M | -1.87M | -1.18M | -2.88M |